

Impact of Direct Acting Antivirals Agents on kidney function in Hepatitis C Virus infected patients with chronic kidney disease

A Thesis

Submitted for partial fulfillment of M.D degree
in Internal Medicine

By

Wedad Adel Mahmoud Abdo

M.B.B.Ch, M.SC

Faculty of Medicine-Ain Shams University

Under Supervision of

Prof. Dr. Iman Ibrahim Sarhan

Professor of Internal Medicine and Nephrology

Faculty of Medicine - Ain-Shams University

Prof. Dr. Osama Mahmoud Kamal

Professor of Internal Medicine and Nephrology

Faculty of Medicine - Ain-Shams University

Prof. Dr. Hayam Ahmed Hebah

Professor of Internal Medicine and Nephrology

Faculty of Medicine - Ain-Shams University

Prof. Dr. Ossama Ashraf Ahmed

Professor of Internal Medicine and Gastroenterology

Faculty of Medicine - Ain-Shams University

Dr. Lina Essam Khedr

Lecturer of Internal Medicine and Nephrology

Faculty of Medicine - Ain-Shams University

Faculty of Medicine

Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the **Most Beneficent** and **Merciful** who gave me the strength to accomplish this work,*

*My deepest gratitude to my supervisor, **Prof. Dr. Iman Ibrahim Sarhan**, Professor of Internal Medicine and Nephrology, Faculty of Medicine - Ain-Shams University, for her valuable guidance and expert supervision, in addition to her great deal of support and encouragement. I really have the honor to complete this work under her supervision.*

*I would like to express my great and deep appreciation and thanks to **Prof. Dr. Hayam Ahmed Hebah**, Professor of Internal Medicine and Nephrology, Faculty of Medicine - Ain-Shams University, for her meticulous supervision, and her patience in reviewing and correcting this work,*

*I must express my deepest thanks to **Prof. Dr. Osama Mahmoud Kamal**, Professor of Internal Medicine and Nephrology, Faculty of Medicine - Ain-Shams University, for guiding me throughout this work and for granting me much of his time. I greatly appreciate her efforts.*

*I can't forget to thank with all appreciation **Prof. Dr. Ossama Ashraf Ahmed**, Professor of Internal Medicine and Gastroenterology, Faculty of Medicine - Ain-Shams University, whom tirelessly and freely gave comments on various drafts of this piece of work,*

*Last but not least my great thanks and gratitude to **Dr. Lina Essam Khedr**, Lecturer of Internal Medicine and Nephrology, Faculty of Medicine - Ain-Shams University, for the efforts and time she has devoted to accomplish this work,*

*Special thanks to my **Parents**, my **Husband** and all my **Family** members for their continuous encouragement, enduring me and standing by me.*

 **Wedad Adel Mahmoud Abdo**

List of Contents

Subject	Page No.
List of Abbreviations.....	i
List of Tables.....	iii
List of Figures	iv
Introduction	1
Aim of the Work.....	4
Review of Literature	
Hepatitis C virus.....	5
HCV induced kidney diseases.....	29
Direct acting antiviral drugs.....	49
Patients and Methods.....	63
Results.....	73
Discussion	105
Summary	115
Conclusions and Recommendations	117
References	119
Arabic Summary	—

List of Abbreviations

Abbr.	Full-term
AASLD	: American Association for the Study of Liver Diseases
AKI	: Acute kidney injury
ALT	: Alanine aminotransferase
APRI	: Aminotransferase/ platelet ratio index
CD	: Cluster of differentiation
CKD	: Chronic kidney disease
DAAs	: Direct-acting antiviral agents
DAMPs	: Damage-associated molecular patterns
EASL	: European Association for the Study of the Liver
ER	: Endoplasmic reticulum
ESRD	: End-stage renal disease
FSGS	: Focal segmental glomerulosclerosis
GFR	: Glomerular filtration rate
HCC	: Hepatocellular carcinoma
HCV	: Hepatitis C virus
HD	: Hemodialysis
HIV	: Human immunodeficiency virus

HRS	: Hepatorenal syndrome
HVPG	: Hepatic venous pressure gradient
IDSA	: Infectious Diseases Society of America
IFN	: Interferon
INR	: International normalized ratio
IRES	: Internal Ribosome Binding Site
KDIGO	: Kidney Diseases Improving Global Outcomes
KT	: Kidney transplantation
MDRD	: Modification of Diet in Renal Disease
MELD	: Model for End-Stage Liver Disease
MPGN	: Membranoproliferative glomerulonephritis
NK	: Natural killer
NS	: Nonstructural
NTPase	: Nucleoside-triphosphatase
OMV/PTV/RTV	Ombitasvir, Paritaprevir, and Ritonavir
PAMPs	: Pathogen-associated molecular patterns
PAT	: Parenteral anti-schistosomal therapy
PEG-IFN	: Pegylated IFN
PLA2R	: Phospholipase A2 receptor
Pr/Cr	: Protein/creatinine

PrOD	: Paritaprevir/ritonavir/ombitasvir plus dasabuvir
RAAS	: Renin-angiotensin-aldosterone system
RBV	: Ribavirin
RF	: Rheumatoid factor
RNA	: Ribonucleic acid
SRB	: Scavenger receptor class B
SVR	: Sustained virological response
TE	: Transient elastography
TIPS	: Transjugular intrahepatic portosystemic shunt
TLR	: Toll-like receptor
TNF	: Tumor necrosis factor
WHO	: World health organization

List of Tables

Table No.	Title	Page No.
Table (1):	Extrahepatic manifestations of HCV infection	28
Table (2):	Histopathological features of hepatitis C virus-related renal involvement.....	38
Table (3):	Brouet classification of cryoglobulinemia.....	42
Table (4):	The four classes of direct-acting antiviral agents.....	52
Table (5):	Recommended direct-acting therapies by eGFR and viral genotype (AASLD/IDSA).....	57
Table (6):	Demographic data of all study population (N=100)	74
Table (7):	Clinical data of all study population (N=100)	75
Table (8):	Baseline investigations of the study population.....	75
Table (9):	Liver and kidney ultrasound of study population (N=100).....	76
Table (10):	Comparison between the two study groups regarding demographic data	77
Table (11):	Comparison between the two groups as regard Clinical data	78
Table (12):	Comparison between the Baseline investigations in both groups	79
Table (13):	Change in renal functions in (OMV/PTV/RTV) group.....	80

Table (14):	Change in lab investigations in (OMV/PTV/RTV) group.....	83
Table (15):	Change in Hemoglobin level in (OMV/PTV/RTV) group.....	84
Table (16):	Change in renal functions in (SOF/DAC) group.....	84
Table (17):	Change in lab investigations in (SOF/DAC) group.....	87
Table (18):	Change in Hemoglobin level in (OMV/PTV/RTV) group.....	88
Table (19):	Comparison between two groups regarding change in eGFR	89
Table (20):	Comparison between two groups regarding change in creatinine level	91
Table (21):	Comparison between two groups regarding change in protein/ creatinine ratio	92
Table (22):	Linear regression analysis for predictors of change in eGFR	92
Table (23):	Comparison between CKD stages regarding change in eGFR and serum creatinine	93
Table (24):	Comparison between side effects in both groups	94
Table (25):	Comparison between the different CKD stages as regard side effects	95
Table (26):	Comparison between hepatic decompensation in both groups	96
Table (27):	Comparison between groups as regard on treatment Anemia	97
Table (28):	Relation between patients received Ribavirin and Anemia	98

Table (29):	Modification in Ribavirin during the study	99
Table (30):	Comparison between diabetics and non-diabetics regarding change in eGFR and serum creatinine	100

List of Figures

Figure No.	Title	Page No.
Figure (1):	Genomic organization of the hepatitis C virus	5
Figure (2):	Function of structural and non structural HCV proteins	7
Figure (3):	Life cycle of HCV in hepatocytes	10
Figure (4):	Prevelence of HCV worldwide	14
Figure (5):	Countries with the highest prevalence of HCV	14
Figure (6):	Natural history of HCV	16
Figure (7):	Stages of liver cirrhosis	19
Figure (8):	Scheme of investigations in suspected HCV infection	21
Figure (9):	Chronic liver disease progression	23
Figure (10):	Factors involved in the pathogenesis of HRS	31
Figure (11):	Inflammatory mediators and pathways that can affect the circulation	33
Figure (12):	Light and electron microscopy of MPGN	43
Figure (13):	History of antiviral drugs	50
Figure (14):	Metabolism of DDAs	51
Figure (15):	The HCV genome and target sites of action for the direct acting antiviral vagents	54

Figure (16): Gender distribution in the study population.....	73
Figure (17): Distribution of CKD stages among the study population.	74
Figure (18): Follow up of eGFR in (OMV/PTV/RTV) group.....	81
Figure (19): Follow up of serum creatinine in (OMV/PTV/RTV) group.....	82
Figure (20): Follow up of eGFR in SOF/DAC group.	85
Figure (21): Follow up of serum creatinine in SOF/DAC group.....	86
Figure (22): Comparison between follow up of eGFR in both groups.....	90
Figure (23): Comparison between follow up of serum creatinine in both groups.....	91
Figure (24): Comparison between CKD stages regarding change in eGFR and serum creatinine	94
Figure (25): Comparison between the two groups as regard anemia.	97
Figure (26): Comparison between the patients received RBV and patients didn't receive RBV as regard anemia.	98
Figure (27): Comparison between diabetic and non diabetic patients as regard eGFR.	101
Figure (28): Comparison between diabetic and non diabetic patients as regard creatinine.	101
Figure (29): Comparison between diabetic and non diabetic patients as regard proteinuria.	102

ABSTRACT

Introduction: Despite the significant link between HCV and CKD progression, most of the patients with CKD infected with HCV remain untreated, because they have historically been difficult to treat due to common adverse effects associated with interferon (IFN), ribavirin, and first generation protease inhibitors. Recently, there have been major advancements in the treatment of HCV with the development of new direct- acting antivirals (DAAs).

Objectives: To evaluate the safety and efficacy of DAAs and their impact on kidney function in CKD patients.

Patients and Methods: We conducted a prospective observational study on 100 CKD patients stages 3-4, receiving treatment for HCV at MASRI (faculty of Medicine Ain Shams University Research Institute), with two different DAAs regimens, completed over six months follow up. Kidney function was followed during and after treatment.

Results: Sustained virological response (SVR) was achieved in all patients. AKI (acute kidney injury) was uncommon; it occurred in three (3%) patients, out of them, two patients showed complete recovery. Adverse events were common (43%), but serious adverse events were uncommon (2%).Improvement of eGFR ($8-15 \text{ ml/min/1.73 m}^2$) and proteinuria was found in both study groups.

Conclusion: DAAs were effective and well- tolerated for HCV infected patients with stage 3-4 chronic kidney disease, where viral clearance caused improvement in eGFR and proteinuria.

Keywords: Hepatitis C virus (HCV), Direct-acting antiviral (DAA), Chronic kidney disease (CKD).

Introduction

Hepatitis C virus (HCV) affects over 70 million people worldwide, corresponding to 1.0% of the global population. Public interest in HCV is growing, especially since the virus can also induce extrahepatic manifestations (in 40–70% of cases) including autoimmunity-related symptoms, metabolic, renal, cardiovascular, central nervous system or lymphoproliferative disorders (*Iliescu et al., 2020*).

The prevalence of HCV infection is highest in Egypt ranging from 6% to 40% with an average of 14%. This is greatly attributable to the era of parenteral anti-schistosomal therapy (PAT) mass- treatment campaigns between the period of 1960-1980 (*El-Zanaty and Way, 2015*).

Hepatitis C virus (HCV) infection is strongly associated with chronic kidney disease (CKD). It is an independent risk factor for developing CKD, and significantly increases morbidity and mortality in patients with CKD (*Shuster et al., 2019*).

It is well recognized that HCV infection can directly, via glomerulonephritis and cryoglobulinemic vasculitis, or indirectly, via hepatic cirrhosis and associated complications of portal hypertension, cause renal dysfunction and large-scale community observational studies have shown that HCV

infection increases the risk for incident chronic kidney disease (CKD) and progression to end-stage renal disease (**Saxena & Terrault. 2016**).

Treatment for HCV infection has changed in the past few years with the introduction of direct-acting antiviral agents (DAAs) that have improved sustained virological response (SVR) compared with pegylated interferon–ribavirin (IFN ± RBV) , even in patients with chronic kidney disease (CKD) (**Pérez de José et al., 2020**).

DAAs directly target viral proteins critical to HCV’s replicative machinery and, when used in combination, produce cure rates of >97%. Despite of recent advances, little is known about the effect of HCV treatment with DAAs on short- or long-term kidney function. Whether or not the association of HCV with rapid CKD progression can be mitigated by HCV treatment has not yet been evaluated in the era of DAA therapies for HCV infection (**Sise et al., 2020**).

In this context, HCV-infected patients with CKD stages 1 [glomerular filtration rate (GFR) > 90 mL/min 1.73 m²], 2 (GFR 60–89 mL/min per 1.73 m²), and 3a (GFR 45–59 mL/min per 1.73 m²) should be considered to receive direct-acting antivirals (DAA), with the goal of slowing the progression of CKD. HCV-infected patients with CKD stages 3b (GFR 30–44 mL/min per 1.73 m²), 4 (GFR 15–29 mL/min